Astellas licenses FibroGen's anemia compounds

FibroGen (South San Francisco, Calif.) granted Astellas (Tokyo:4503) exclusive rights to develop and market FG-2216, FG-4592 and other hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors for anemia in Europe, the Commonwealth of Independent States, the Middle East and South Africa. FibroGen will receive $300 million up front and is eligible for $465 million in milestones. Astellas also will buy $50 million in FibroGen shares. The partners will share development costs in North America and Europe. ...